Theralase Technologies Inc. V.TLT

Science stuff

[DJDawg]

Just doing some random reading and found this. Likely posted before. It is an article talking about the over-expression of transferrin receptors on cancer vs normal cells. This receptor is what would take up Rutherrin based molecules preferentially and then, when activated by xray or light, cause cell death. I liked the image (link below) which showed the dramatic difference in TFR1 expression between normal and cancer cells. Makes you appreciate how powerful TLT's compounds may be in terms of targetting proliferating cancers selectively. Truly could be game changer.

https://postimg.cc/G4NNHz0V

image is from
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048407/pdf/ajcr0008-0916.pdf

[Eoganacht]

Hi Dawg - I think there are 2 key features to Theralase's pdt which makes it a game changer - the selective uptake of the photosensitizer by cancer cells (which, as you note below, rely on the over-expression of transferrin receptors on cancer vs normal cells) and the inducement of immunogenic cell death, which establishes antitumour immunity, so that any cancer cells, of the type

[DJDawg]

Fascinating. Thanks for sharing.

[CancerSlayer]

  It's encouraging to know this same cancer-killing mechanism of action & its resultant immune response will also play a strong role in our upcoming GBM trial.    Not only does Rutherrin effectively cross the blood-brain barrier to destroy such a deep-seated brain tumor, an earlier study published in 5/2019 by our very own Dr. Mandel, Dr. Lilge et al provided solid